[Skip to Navigation]
Sign In
Correction
May 17, 2022

Error in Nonauthor Collaborators

JAMA Netw Open. 2022;5(5):e2215958. doi:10.1001/jamanetworkopen.2022.15958

In the Original Investigation titled “Efficacy of Losartan in Hospitalized Patients With COVID-19–Induced Lung Injury: A Randomized Clinical Trial,”1 published March 16, 2022, Nastasia James was missing from the list of Angiotensin Receptor Blocker Based Lung Protective Strategies for Inpatients With COVID-19 (ALPS-IP) Investigators. This article has been corrected.1

Reference
1.
Puskarich  MA, Ingraham  NE, Merck  LH,  et al; Angiotensin Receptor Blocker Based Lung Protective Strategies for Inpatients With COVID-19 (ALPS-IP) Investigators.  Efficacy of losartan in hospitalized patients with COVID-19–induced lung injury: a randomized clinical trial.   JAMA Netw Open. 2022;5(3):e222735. doi:10.1001/jamanetworkopen.2022.2735PubMedGoogle ScholarCrossref
×